Table 2.
Comparison of genotype frequencies of miRNA polymorphisms between patients and controls
| Genotypes | Controls (n = 228) |
IF ≥ 2 (n = 118) |
AOR (95% CI)a | Pa | IF ≥ 3 (n = 106) | AOR (95% CI)a | Pa | IF ≥ 4 (n = 75) | AOR (95% CI)a | Pa |
|---|---|---|---|---|---|---|---|---|---|---|
| miR-25 rs1527423 T>C | ||||||||||
| TT | 179 (78.5) | 94 (79.7) | 1.000 (reference) | 84 (79.25) | 1.000 (reference) | 57 (76.00) | 1.000 (reference) | |||
| TC | 46 (20.2) | 23 (19.5) | 0.947 (0.541–1.658) | 0.849 | 21 (19.81) | 0.968 (0.542–1.728) | 0.913 | 17 (22.67) | 1.146 (0.608–2.159) | 0.673 |
| CC | 3 (1.3) | 1 (0.8) | 0.632 (0.065–6.169) | 0.693 | 1 (0.94) | 0.709 (0.073–6.931) | 0.767 | 1 (1.33) | 1.044 (0.106–10.249) | 0.971 |
| Dominant (TT vs TC+CC) | 0.927 (0.535–1.606) | 0.788 | 0.952 (0.540–1.679) | 0.865 | 1.139 (0.613–2.116) | 0.680 | ||||
| Recessive (TT+TC vs CC) | 0.639 (0.066–6.218) | 0.700 | 0.713 (0.073–6.959) | 0.771 | 1.014 (0.104–9.927) | 0.991 | ||||
| HWE P | 0.981 | 0.753 | 0.804 | 0.832 | ||||||
| miR-32 rs7041716 C>A | ||||||||||
| CC | 187 (82.0) | 94 (79.7) | 1.000 (reference) | 85 (80.19) | 1.000 (reference) | 58 (77.33) | 1.000 (reference) | |||
| CA | 39 (17.1) | 22 (18.6) | 1.123 (0.629–2.004) | 0.695 | 19 (17.92) | 1.069 (0.582–1.963) | 0.829 | 16 (21.33) | 1.315 (0.683–2.530) | 0.413 |
| AA | 2 (0.9) | 2 (1.7) | 1.893 (0.262–13.686) | 0.527 | 2 (1.89) | 2.072 (0.286–15.003) | 0.471 | 1 (1.33) | 1.446 (0.128–16.310) | 0.766 |
| Dominant (CC vs CA+AA) | 1.163 (0.663–2.040) | 0.600 | 1.121 (0.623–2.016) | 0.704 | 1.322 (0.697–2.508) | 0.392 | ||||
| Recessive (CC+CA vs AA) | 1.876 (0.260–13.511) | 0.532 | 2.064 (0.286–14.894) | 0.472 | 1.390 (0.124–15.610) | 0.790 | ||||
| HWE P | 0.983 | 0.594 | 0.45 | 0.906 | ||||||
| miR-125a rs12976445 C>T | ||||||||||
| CC | 170 (74.6) | 98 (83.1) | 1.000 (reference) | 87 (82.08) | 1.000 (reference) | 63 (84.00) | 1.000 (reference) | |||
| CT | 52 (22.8) | 20 (16.9) | 0.680 (0.383–1.208) | 0.188 | 19 (17.92) | 0.734 (0.408–1.321) | 0.303 | 12 (16.00) | 0.633 (0.316–1.266) | 0.196 |
| TT | 6 (2.6) | 0 (0.0) | N/A | 0.995 | 0 (0.00) | 0.000 (0.000–0.000) | 0.995 | 0 (0.00) | 0.000 (0.000–0.000) | 0.993 |
| Dominant (CC vs CT+TT) | 0.610 (0.346–1.075) | 0.087 | 0.658 (0.368–1.177) | 0.158 | 0.568 (0.286–1.130) | 0.107 | ||||
| Recessive (CC+CT vs TT) | N/A | 0.995 | N/A | 0.995 | N/A | 0.993 | ||||
| HWE P | 0.408 | 0.315 | 0.311 | 0.448 | ||||||
| miR-222 rs34678647 G>T | ||||||||||
| GG | 133 (58.3) | 62 (52.5) | 1.000 (reference) | 56 (52.83) | 1.000 (reference) | 39 (52.00) | 1.000 (reference) | |||
| GT | 79 (34.6) | 48 (40.7) | 1.320 (0.825–2.112) | 0.247 | 42 (39.62) | 1.284 (0.787–2.096) | 0.317 | 31 (41.33) | 1.343 (0.775–2.327) | 0.294 |
| TT | 16 (7.0) | 8 (6.8) | 1.030 (0.415–2.560) | 0.949 | 8 (7.55) | 1.144 (0.457–2.859) | 0.774 | 5 (6.67) | 0.999 (0.340–2.938) | 0.999 |
| Dominant (GG vs GT+TT) | 1.273 (0.813–1.993) | 0.291 | 1.262 (0.792–2.009) | 0.327 | 1.288 (0.761–2.179) | 0.346 | ||||
| Recessive (GG+GT vs TT) | 0.944 (0.391–2.279) | 0.898 | 1.054 (0.435–2.553) | 0.908 | 0.911 (0.321–2.589) | 0.861 | ||||
| HWE P | 0.371 | 0.752 | 0.974 | 0.726 | ||||||
IF, implantation failure; AOR, adjusted odds ratio; for AOR, OR adjusted by age of participants; 95% CI, 95% confidence interval; N/A, not applicable
aAdjusted by age